← Back to Search

Radiation Therapy

CyberKnife Radiosurgery for Prostate Cancer

Phase 2
Waitlist Available
Led By Donald B Fuller, M.D.
Research Sponsored by CyberKnife Centers of San Diego
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histologically confirmed recurrent adenocarcinoma of the prostate, clinical stage T1 - T3 (AJCC 6th Edition)
Karnofsky performance status >80
Must not have
Radical surgery for carcinoma of the prostate
History of inflammatory bowel disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will help determine if a new type of radiation treatment, called prostate radiosurgery, is more effective than other salvage treatments for locally recurrent prostate cancer.

Who is the study for?
Men with prostate cancer that has come back locally after previous radiotherapy can join this trial. They should have no distant spread of cancer, no lymph node involvement, and a life expectancy over 5 years. Participants need to be fairly active (Karnofsky score >80) and it must be more than 2 years since their last radiotherapy.
What is being tested?
The study is testing CyberKnife Radiosurgery, which targets radiation doses precisely at the tumor with fewer treatments but higher dose each time. It's compared against other salvage treatments like brachytherapy or surgery to see if it offers any benefits.
What are the potential side effects?
Potential side effects may include damage to surrounding tissues leading to gastrointestinal or urinary issues due to high-dose radiation in focused areas. The exact side effects will vary based on individual patient factors.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My prostate cancer has come back and is at an early to mid-stage.
Select...
I can carry out normal activities without assistance.
Select...
My cancer has not spread to my lymph nodes.
Select...
My cancer has not spread to distant parts of my body.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had major surgery for prostate cancer.
Select...
I have a history of inflammatory bowel disease.
Select...
My cancer has spread to nearby lymph nodes.
Select...
My cancer has spread to distant parts of my body.
Select...
I have minor or no long-term stomach or urinary side effects from past radiation.
Select...
My cancer is at stage T4 according to the AJCC 6th Edition.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: CyberKnife RadiosurgeryExperimental Treatment1 Intervention
Single arm study using CyberKnife radiosurgery to treat recurrent prostate cancer patients that have already received external beam radiotherapy.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CyberKnife Radiosurgery
2007
N/A
~10

Find a Location

Who is running the clinical trial?

CyberKnife Centers of San DiegoLead Sponsor
1 Previous Clinical Trials
258 Total Patients Enrolled
1 Trials studying Prostate Cancer
258 Patients Enrolled for Prostate Cancer
Donald B Fuller, M.D.Principal InvestigatorCyberKnife Centers of San Diego
1 Previous Clinical Trials
258 Total Patients Enrolled
1 Trials studying Prostate Cancer
258 Patients Enrolled for Prostate Cancer

Media Library

CyberKnife Radiosurgery (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT00851916 — Phase 2
Prostate Cancer Research Study Groups: CyberKnife Radiosurgery
Prostate Cancer Clinical Trial 2023: CyberKnife Radiosurgery Highlights & Side Effects. Trial Name: NCT00851916 — Phase 2
CyberKnife Radiosurgery (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00851916 — Phase 2
~1 spots leftby Nov 2025